# Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

> **NCT06526000** · — · COMPLETED · sponsor: **Novartis** · enrollment: 326 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis
- Clinically Isolated Syndrome
- Relapsing-remitting Multiple Sclerosis
- Secondary Progressive Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06526000
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-11
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 326 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06526000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06526000, "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06526000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*